MedTrace Logo

Renal Blood Flow Measurement With Positron Emission Tomography (PET)

NCT00714142 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-04-19

No results posted yet for this study

Summary

Two investigational chemical tracers, 62Cu-ethylglyoxal bis(thiosemicarbazone) (62Cu-ETS) and 15O-water, will be used in this study to look at how blood moves through the kidneys. The purpose of the study is to see if 62Cu-ETS is effective in showing the blood supply to the kidneys compared to 15O-water. The tracer mixes with the blood and moves through the body. Using positron emission tomography (PET scan) the researchers can see the tracer and can learn more about how the blood moves through the kidneys. The study invites participants who are healthy, without any heart or kidney disease, patients who have kidney disease that require dialysis, and patients who may have a blockage in one of the arteries supplying blood to the kidneys.

Conditions

  • Renal Failure
  • Renal Artery Stenosis

Interventions

DRUG

62Cu-ethylglyoxal bis(thiosemicarbazone)

15-25 mCi, IV

DRUG

15O-water

10-20 mCi, IV

PROCEDURE

Positron Emission Tomography

PET Scan

Sponsors & Collaborators

  • University of Wisconsin, Madison

    collaborator OTHER

  • Jeffrey L. Lacy

    lead INDUSTRY

Principal Investigators

  • Jeffrey L Lacy, PhD · Proportional Technologies, Inc.

  • Charles K Stone, MD · University of Wisconsin, Madison

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00714142 on ClinicalTrials.gov